Regards Medicaid managed care coverage of pharmacogenomic testing

This bill requires Medicaid managed care organizations to cover pharmacogenomic testing for Medicaid enrollees diagnosed with depression or anxiety when a prescriber is considering changes to their medication due to known gene-drug interactions. The testing must meet specific criteria, including Medicare coverage under a local determination, and managed care plans can only impose prior authorization if they provide a clear, timely process requiring minimal documentation. The bill also establishes enforcement measures, including fines and potential contract termination, for organizations that fail to comply with these coverage requirements.